Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech World Maldives.
Press releases published on October 14, 2025
WISeKey Announces 9M 2025 Preliminary Revenue and Key Financial Metrics
WISeKey Announces 9M 2025 Preliminary Revenue and Key Financial Metrics Reports preliminary unaudited 9M 2025 revenue of $10.6 million, +39% year on year growth Reaffirms its FY 2025 Revenue Guidance of $18 to $21.0 Million, Representing a 51%–76% Year-on- …
Digital Check Introduces Next-Generation TellerScan® TS250 UV Ultraviolet Scanner
NORTHBROOK, Ill., Oct. 14, 2025 (GLOBE NEWSWIRE) -- The TellerScan TS250 UV is the latest in ultraviolet image capture from Digital Check Corp., a high-speed UV cheque scanner that succeeds the company’s best-selling TellerScan TS240 model. The new TS250 …
Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, …
DataGlobal Hub Announces Exclusive Elite Membership for Senior Data and AI Leaders
PHOENIX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- DataGlobal Hub, a global media company dedicated to Data and Artificial Intelligence(AI) news, information and resources with a clear vision of creating the most prestigious and trusted network of AI professionals …
Apollomics, Inc. Company Operational Continuity Update
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative …
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic …